Last reviewed · How we verify
Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
RATIONALE: Sorafenib tosylate and pravastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of liver cancer by blocking blood flow to the tumor. It is not yet known whether sorafenib tosylate is more effective when given alone or together with pravastatin in treating patients with liver cancer and cirrhosis. PURPOSE: This randomized phase III trial is studying sorafenib tosylate given together with pravastatin to see how well it works compared with giving sorafenib tosylate alone in treating patients with liver cancer and cirrhosis.
Details
| Lead sponsor | Federation Francophone de Cancerologie Digestive |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 323 |
| Start date | 2010-02 |
| Completion | 2015-09 |
Conditions
- Liver Cancer
Interventions
- pravastatin sodium
- sorafenib tosylate
Primary outcomes
- Overall survival — 2014
Countries
France